Select a medication above to begin.
Evista
raloxifene
Black Box Warnings .
Venous Thromboembolism Risk
contraindicated in women w/ active or past hx of venous thromboembolism due to incr. venous thromboembolism risk
Fatal Stroke Risk
incr. risk of death from stroke in postmenopausal women w/ documented CHD or risk factors for major coronary events; consider risk/benefit in women w/ stroke risk
Adult Dosing .
Dosage forms: TAB: 60 mg
osteoporosis prevention, postmenopausal
- [60 mg PO qd]
- Info: calcium and vitamin D supplementation recommended if inadequate intake; D/C tx >72h before surgery w/ VTE risk
osteoporosis tx, postmenopausal
- [60 mg PO qd]
- Info: calcium and vitamin D supplementation recommended if inadequate intake; D/C tx >72h before surgery w/ VTE risk
breast CA prevention
- [60 mg PO qd]
- Info: for postmenopausal women at high risk for invasive breast CA; D/C tx >72h before surgery w/ VTE risk
renal dosing
- [see below]
- CrCl >50: no adjustment; CrCl <50: not defined, caution advised
- HD/PD: not defined
hepatic dosing
- [see below]
- hepatic impairment: not defined, caution advised
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.